CeriBell (NASDAQ:CBLL) Reaches New 52-Week Low – Here’s What Happened

CeriBell (NASDAQ:CBLL)’s stock price reached a new 52-week low during mid-day trading on Monday . The company traded as low as $22.81 and last traded at $22.91, with a volume of 47261 shares trading hands. The stock had previously closed at $24.29.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Canaccord Genuity Group started coverage on CeriBell in a report on Tuesday, November 5th. They set a “buy” rating and a $30.00 price target on the stock. Bank of America began coverage on shares of CeriBell in a research note on Tuesday, November 5th. They issued a “buy” rating and a $32.00 price target for the company. TD Cowen increased their price objective on shares of CeriBell from $31.00 to $36.00 and gave the company a “buy” rating in a research report on Monday, December 9th. Canaccord Genuity Group lifted their price objective on shares of CeriBell from $31.00 to $33.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. Finally, JPMorgan Chase & Co. assumed coverage on CeriBell in a report on Tuesday, November 5th. They issued an “overweight” rating and a $32.00 target price on the stock. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $32.60.

CeriBell Stock Performance

The firm’s 50-day simple moving average is $27.27.

CeriBell (NASDAQ:CBLL) last posted its earnings results on Tuesday, November 12th. The company reported ($1.85) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($1.03). The firm had revenue of $17.20 million during the quarter, compared to analyst estimates of $17.06 million. As a group, analysts predict that CeriBell will post -2.46 EPS for the current year.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.